We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Multiplex Immunoassay Developed for Chagas Disease

By LabMedica International staff writers
Posted on 21 Apr 2016
Different tests are available for the diagnosis of Chagas disease in the clinic or for screening of blood donations. More...
Direct detection of parasite Trypanosoma cruzi in the blood is performed by microscopy, hemoculture, xenodiagnoses, or detection of the parasite’s nucleic acids.

These assays are highly specific but lack sensitivity in the chronic stage during which parasites load in the blood is reduced and therefore, diagnosis of T. cruzi infection is usually made indirectly by the detection of specific antibodies to T. cruzi antigens using enzyme-linked immunosorbent assays.

Scientists from InfYnity Biomarkers (Lyon, France) working with their Brazilian colleagues tested 248 positive samples T. cruzi, 94 unscreened blood donors’ samples from non-endemic area, 49 seronegative blood donors, 7 false-positive and 3 doubtful samples. They designed a novel array of twelve antigens and printed these antigens onto 96-well plates using a sciFLEXARRAYER printing system (SCIENION; Berlin, Germany). Multi- cruzi Chagas ELISA assays were performed and each plate was imaged then analyzed using the SensoSpot Microarray Analyzers (Sensovation; Radolfzell, Germany).

Among the 200 cardiomyopathy samples, only 194 could be characterized as either negative (67%) or positive (33%) by polymerase chain reaction (PCR). Additionally, among the 48 screening-positive blood donors, 34 were PCR negative (71%) and 14 were PCR positive (29%). PCR techniques were different for both populations. The observed reactivities were analyzed to propose a decision-tree algorithm that correctly classifies all the samples, with the potential to discriminate false-positive results and sticky samples. The team observed that antibodies levels (Sum of all antigens) were significantly higher for PCR positive than for PCR negative samples in all studied groups with Multi-cruzi Chagas ELISA.

The authors concluded that the results described in their study indicate that the Multi-cruzi improves the serological confirmation of Chagas disease. Moreover, the “sum of all antigens” detected by Multi-cruzi could reflect parasitemia level in patients, similar to PCR signals, and could serve as an indicator of parasite clearance in longitudinal follow- ups. Validation of this assay is still required on an independent large collection of well-characterized samples including typical false-reactive samples such as Leishmaniasis. The study was published on April 1, 2016, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
InfYnity Biomarkers
SCIENION
Sensovation


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.